Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab

Rituximab, a murine–human chimera, is the first monoclonal antibody (mAb) developed as a therapeutic agent to target CD20 protein. Its Fab domain and its interaction with CD20 have been extensively studied and high-resolution atomic models obtained by X-ray diffraction or cryo-electron microscopy ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Belviso, Benny Danilo, Mangiatordi, Giuseppe Felice, Alberga, Domenico, Mangini, Vincenzo, Carrozzini, Benedetta, Caliandro, Rocco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037831/
https://www.ncbi.nlm.nih.gov/pubmed/35480889
http://dx.doi.org/10.3389/fmolb.2022.823174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037831/
https://www.ncbi.nlm.nih.gov/pubmed/35480889
http://dx.doi.org/10.3389/fmolb.2022.823174

Ejemplares similares